ReviewDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy2016
Antibiotic resistance in Burkholderia species.
Review in Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 217 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
217 citing papers in PubMed, 384 citations in OpenAlex.
- Regulation of Type VI Secretion Systems of Burkholderia during transition to intracellular lifestyle.EMBO reports · 2026Article
- Discovery of repurposed drugs that disrupt intracellular replication of Burkholderia pseudomallei and Burkholderia mallei and protect against lethal aerosol infection.PLoS pathogens · 2026Article
- Burkholderia arboris bacteremia initially identified as Burkholderia cepacia complex: a genome-based case report.Archives of microbiology · 2026Article
- Evaluation of the antimicrobial and antibiofilm activities of aztreonam-avibactam against the Burkholderia cepacia complex.Folia microbiologica · 2026Article
- Thioredoxin Reductase as a Target for Antibacterial Gold Compounds in Burkholderia cenocepacia: Disclosing the Molecular Basis of Enzyme Inhibition.Chembiochem : a European journal of chemical biology · 2026Article
- Draft genome sequences ofMicrobiology resource announcements · 2026Article
- Emergence, evolution, and global dissemination of antimicrobial resistance: A One Health review.Archives of microbiology · 2026Review
- Genomic Insights into a New Burkholderia cenocepacia Sequence Type Linked to Cepacia Syndrome in Cystic Fibrosis.Current microbiology · 2026Article
- Is it okay to use a commercially available AST forJournal of clinical microbiology · 2026Article
- Article
- Human infections caused by pathogenic Burkholderia: current clinical challenges and future perspectives.Infection · 2026Review
- Secretion systems shaping host-pathogen interactions in Burkholderia species.Applied microbiology and biotechnology · 2026Review
- Functional analysis ofMicrobiology spectrum · 2026Article
- Article
- Hydrodynamics Shape Antibiotic Resistance in Wastewater-Impacted River Biofilms.Microbial ecology · 2026Article
- Laboratory strategies for the identification of Burkholderia species: From classical phenotyping to advanced genomic and proteomic approaches.Antonie van Leeuwenhoek · 2026Review
- Co-culture metabolomics: a powerful tool for uncovering host-pathogen phenotypes drivingmSystems · 2026Article
- Bacterial quorum-sensing systems in cell-cell communication.FEMS microbiology reviews · 2026Review
- PersistentClinical case reports · 2026Article
- Isolation ofIDCases · 2026Article
157 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The genus Burkholderia comprises metabolically diverse and adaptable Gram-negative bacteria, which thrive in often adversarial environments. A few members of the genus are prominent opportunistic pathogens. These include Burkholderia mallei and Burkholderia pseudomallei of the B. pseudomallei complex, which cause glanders and melioidosis, respectively. Burkholderia cenocepacia, Burkholderia multivorans, and Burkholderia vietnamiensis belong to the Burkholderia cepacia complex and affect mostly cystic fibrosis patients. Infections caused by these bacteria are difficult to treat because of significant antibiotic resistance. The first line of defense against antimicrobials in Burkholderia species is the outer membrane penetration barrier. Most Burkholderia contain a modified lipopolysaccharide that causes intrinsic polymyxin resistance. Contributing to reduced drug penetration are restrictive porin proteins. Efflux pumps of the resistance nodulation cell division family are major players in Burkholderia multidrug resistance. Third and fourth generation β-lactam antibiotics are seminal for treatment of Burkholderia infections, but therapeutic efficacy is compromised by expression of several β-lactamases and ceftazidime target mutations. Altered DNA gyrase and dihydrofolate reductase targets cause fluoroquinolone and trimethoprim resistance, respectively. Although antibiotic resistance hampers therapy of Burkholderia infections, the characterization of resistance mechanisms lags behind other non-enteric Gram-negative pathogens, especially ESKAPE bacteria such as Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.